237 related articles for article (PubMed ID: 18757665)
1. Endometrial effects of tibolone in elderly, osteoporotic women.
Ettinger B; Kenemans P; Johnson SR; Mol-Arts M; Van Os S; Seifert W; Verweij PJ; Cummings SR
Obstet Gynecol; 2008 Sep; 112(3):653-9. PubMed ID: 18757665
[TBL] [Abstract][Full Text] [Related]
2. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
3. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy.
Perez-Medina T; Bajo-Arenas J; Haya J; Sanfrutos L; Iniesta S; Bueno B; Castelo-Branco C
Menopause; 2003; 10(6):534-7. PubMed ID: 14627862
[TBL] [Abstract][Full Text] [Related]
4. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
Langer RD; Landgren BM; Rymer J; Helmond FA;
Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
[TBL] [Abstract][Full Text] [Related]
5. Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women.
Archer DF; Hendrix S; Ferenczy A; Felix J; Gallagher JC; Rymer J; Skouby SO; den Hollander W; Stathopoulos V; Helmond FA;
Fertil Steril; 2007 Oct; 88(4):866-78. PubMed ID: 17548089
[TBL] [Abstract][Full Text] [Related]
6. Tibolone and osteoporosis.
Lazovic G; Radivojevic U; Milosevic V; Lazovic A; Jeremic K; Glisic A
Arch Gynecol Obstet; 2007 Dec; 276(6):577-81. PubMed ID: 17605023
[TBL] [Abstract][Full Text] [Related]
7. Endometrial effects of tibolone.
Archer DF; Hendrix S; Gallagher JC; Rymer J; Skouby S; Ferenczy A; den Hollander W; Stathopoulos V; Helmond FA
J Clin Endocrinol Metab; 2007 Mar; 92(3):911-8. PubMed ID: 17192288
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
Hudita D; Posea C; Ceausu I; Rusu M
Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
[TBL] [Abstract][Full Text] [Related]
9. Effects of tibolone on the endometrium.
Völker W; Coelingh Bennink HJ; Helmond FA
Climacteric; 2001 Sep; 4(3):203-8. PubMed ID: 11588943
[TBL] [Abstract][Full Text] [Related]
10. Carcinoma of the endometrium in patients treated with tibolone.
Yazigi R; Sahid S; Contreras L; Rodriguez T
Gynecol Oncol; 2004 May; 93(2):568-70. PubMed ID: 15099984
[TBL] [Abstract][Full Text] [Related]
11. Unopposed estradiol therapy in postmenopausal women: results from two randomized trials.
Steiner AZ; Xiang M; Mack WJ; Shoupe D; Felix JC; Lobo RA; Hodis HN
Obstet Gynecol; 2007 Mar; 109(3):581-7. PubMed ID: 17329508
[TBL] [Abstract][Full Text] [Related]
12. [Is the clinical profile of women treated with tibolone similar to that of women receiving a classical estrogen-progestogen therapy? Data from a nationwide survey in France].
Jamin C; Bourg F; Legeai J; Senoussi S
Gynecol Obstet Fertil; 2006 Mar; 34(3):224-32. PubMed ID: 16513401
[TBL] [Abstract][Full Text] [Related]
13. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
[TBL] [Abstract][Full Text] [Related]
14. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol.
Johnson SR; Ettinger B; Macer JL; Ensrud KE; Quan J; Grady D
Obstet Gynecol; 2005 Apr; 105(4):779-87. PubMed ID: 15802405
[TBL] [Abstract][Full Text] [Related]
15. Cause of vaginal bleeding in postmenopausal women taking tibolone.
Ginsburg J; Prelevic GM
Maturitas; 1996 May; 24(1-2):107-10. PubMed ID: 8794441
[TBL] [Abstract][Full Text] [Related]
16. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy.
Bruce D; Robinson J; Rymer J
Climacteric; 2004 Sep; 7(3):261-6. PubMed ID: 15669550
[TBL] [Abstract][Full Text] [Related]
18. Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women.
Berning B; van Kuijk C; Bennink HJ; Fauser BC
Maturitas; 2000 Apr; 35(1):81-8. PubMed ID: 10802404
[TBL] [Abstract][Full Text] [Related]
19. Significance of "normal" endometrial cells in cervical cytology from asymptomatic postmenopausal women receiving hormone replacement therapy.
Montz FJ
Gynecol Oncol; 2001 Apr; 81(1):33-9. PubMed ID: 11277646
[TBL] [Abstract][Full Text] [Related]
20. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
Beral V; Bull D; Reeves G;
Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
